Related Experiment Video

Updated: May 25, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

CD200R signaling in tumor tolerance and inflammation: A tricky balance

Tomasz P Rygiel1, Linde Meyaard

  • 1Department of Immunology, University Medical Center Utrecht, 3584 EA Utrecht, The Netherlands.

Current Opinion in Immunology
|January 24, 2012
PubMed

Insights

Blocking CD200-CD200 receptor interactions can enhance anti-tumor immunity. This strategy may benefit cancer treatment, even in tumors not expressing CD200, but requires careful consideration in inflammation-dependent cancers.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Therapeutics

Background:

  • The CD200-CD200 receptor (CD200R) pathway normally suppresses immune responses to prevent inflammation.
  • CD200 is often expressed on human tumors, correlating with disease progression.
  • Blocking this inhibitory pathway is being explored to enhance anti-tumor immunity.

Purpose of the Study:

  • To discuss the dual role of CD200 in cancer immunity.
  • To evaluate the potential of CD200 blockade as a cancer therapeutic strategy.
  • To highlight considerations for CD200 blockade in different cancer types.

Main Methods:

  • Literature review and discussion of existing data on CD200 function in infection and cancer.
  • Analysis of CD200 expression in healthy tissues and malignancies.
  • Consideration of therapeutic implications of CD200 pathway modulation.

Main Results:

  • CD200 expressed on tumors and healthy tissues can suppress anti-tumor immune responses.
  • CD200 blockade is a promising strategy to augment anti-tumor immunity.
  • The efficacy of CD200 blockade may depend on the tumor's relationship with inflammation.

Conclusions:

  • CD200 blockade offers a potential therapeutic avenue to enhance anti-tumor responses.
  • This approach is not limited to treating tumors that express CD200.
  • Careful patient selection is needed, as CD200 blockade might promote growth in inflammation-dependent cancers.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...